Video

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

Author(s):

Joshua Richter, MD

In Partnership With:

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Joshua Richter, MD, an assistant professor of medicine, and a hematologist/oncologist at Mount Sinai Hospital, discusses the importance of optimizing available therapies in multiple myeloma. 

Historically, multiple myeloma was thought to be an incurable disease, says Richter. ​However, ​multiple advances in the field have pushed the field closer to developing a cure for patients.  

In addition to conducting more clinical trials and evaluating novel regimens, it is necessary to optimize available therapies, Richter adds. 

Utilizing a multiomic approach may allow the field to optimize existing approaches, ​and provide precision medicine to patients with multiple myeloma, Richter concludes. 

Related Videos
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jorge E. Cortes, MD
Nicolas Girard, MD
Sunil Adige, MD
Minoo Battiwalla, MD, MS
Samuel J. Klempner, MD
Related Content
Multiple Myeloma - stock.adobe.com
October 18th 2024

Selinexor Receives Approval in South Korea for Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Edmond Chan, MBChB, MD, EMEA of Johnson & Johnson
October 10th 2024

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

Matthew Galsky, MD
February 12th 2024

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

Joseph A. Sparano, MD, of Mount Sinai
October 7th 2024

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29